These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 10218669)

  • 1. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.
    Kapur P; Selim MA; Roy LC; Yegappan M; Weinberg AG; Hoang MP
    Mod Pathol; 2005 Feb; 18(2):197-204. PubMed ID: 15467715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
    Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Patereli A; Stratigos A; Katsambas A
    J Am Acad Dermatol; 2007 May; 56(5):815-24. PubMed ID: 17437889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
    Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
    Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p-27 (kip1) in nevi and melanomas.
    Morgan MB; Cowper SE
    Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study.
    Garrido-Ruiz MC; Requena L; Ortiz P; Pérez-Gómez B; Alonso SR; Peralto JL
    Mod Pathol; 2010 Sep; 23(9):1215-24. PubMed ID: 20543820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors.
    Garola R; Singh V
    Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.
    Maldonado JL; Timmerman L; Fridlyand J; Bastian BC
    Am J Pathol; 2004 May; 164(5):1783-7. PubMed ID: 15111324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1 expression in dysplastic nevi: an immunohistochemical study.
    Ewanowich C; Brynes RK; Medeiros L; McCourty A; Lai R
    Arch Pathol Lab Med; 2001 Feb; 125(2):208-10. PubMed ID: 11175636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
    Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma.
    Vollmer RT
    Am J Clin Pathol; 2004 Oct; 122(4):499-505. PubMed ID: 15487445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases.
    Harvell JD; Bastian BC; LeBoit PE
    Am J Surg Pathol; 2002 May; 26(5):654-61. PubMed ID: 11979096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
    Ma SA; O'Day CP; Dentchev T; Takeshita J; Ridky TW; Seykora JT; Chu EY
    J Cutan Pathol; 2019 May; 46(5):310-316. PubMed ID: 30666677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization.
    Wettengel GV; Draeger J; Kiesewetter F; Schell H; Neubauer S; Gebhart E
    Int J Oncol; 1999 Jun; 14(6):1177-83. PubMed ID: 10339676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.